H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis

Trial Profile

H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Finasteride (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Acronyms H-36371
  • Most Recent Events

    • 14 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as the funding was not available.
    • 17 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top